What is Cresilon?
Established in 2010 and headquartered in Brooklyn, United States, Cresilon is at the forefront of developing innovative hemostatic medical devices. The company leverages its proprietary hydrogel technology to create solutions for critical medical needs, positioning itself as a key player in the medical device sector. Cresilon's commitment to advancing healthcare through technological innovation is evident in its product development pipeline and its strategic approach to market penetration.
How much funding has Cresilon raised?
Cresilon has raised a total of $68.8M across 3 funding rounds:
Debt
$350K
Series A
$38.5M
Other Financing Round
$25M
Debt (2020): $350K with participation from PPP
Series A (2021): $38.5M, investors not publicly disclosed
Other Financing Round (2022): $25M supported by Paulson Investment Company
Key Investors in Cresilon
Paulson Investment Company
Paulson Investment Company, LLC is a highly esteemed investment banking firm focused on the small to mid-cap markets, known for leveraging capital markets capabilities to aid clients in achieving strategic and financial objectives.
PPP
Public-Private Partnership
What's next for Cresilon?
With the recent injection of capital, Cresilon is poised for accelerated growth and further development of its hemostatic medical device portfolio. The strategic investment is expected to fuel advancements in manufacturing capabilities, research and development, and market expansion initiatives. This funding will likely enable Cresilon to solidify its position in the biotechnology and medical device industries, potentially leading to new product launches and broader adoption of its hydrogel technology in clinical settings.
See full Cresilon company page
